Breaking Silence Through Story: A Narrative Medicine Intervention for Parents of Children With Urogenital Conditions
Launched by SARAH SCHLEGEL · May 22, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial, called "Breaking Silence Through Story," is looking to see if a journaling program can help reduce stress and anxiety in parents of children with certain urogenital conditions, such as differences of sex development and hypospadias. The researchers want to find out if guided journaling can make parents feel less anxious and gather their thoughts on how helpful group writing activities might be for support in the future.
To participate, parents or legal guardians must have a child aged 0-17 with one of these conditions and be able to read and understand English. They will start by filling out a brief anxiety questionnaire, receive a journal with prompts to help them express their feelings over about five weeks, and then complete the questionnaire again. Finally, they will take part in a 45-minute interview to discuss their experiences with journaling and how it impacted their stress levels. This trial is not yet recruiting participants, but it's a great opportunity for parents seeking support in managing their emotions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Parent or legal guardian of a child (age 0-17 years) diagnosed with a urogenital condition (differences of sex development and/or hypospadias)
- • Able to read and understand English
- • Child receives care at Boston Children's Hospital
- • Willing to complete a guided journaling intervention (through writing or dictation) over a period of approximately 5 weeks
- • Willing to participate in a 45 minute follow-up interview
- • Able to provide informed consent
- Exclusion Criteria:
- • Parent/guardian with severe psychiatric disorder that would interfere with participation as determined by referring physician
- • Parent/guardian unable to complete either written journaling activities or dictation
- • Inability to provide informed consent
About Sarah Schlegel
Sarah Schlegel is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a strong focus on enhancing clinical methodologies and ensuring rigorous compliance with regulatory standards, Sarah leads initiatives that bridge the gap between scientific discovery and practical application. Her collaborative approach fosters partnerships with healthcare professionals and research institutions, driving forward the development of novel treatments across various therapeutic areas. Passionate about patient-centric research, Sarah Schlegel is devoted to fostering an environment that emphasizes safety, efficacy, and ethical considerations in clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported